patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_547729 | REC_0014701 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.3 | 60 | male | 0 | 43 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:36:00.893361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467482 | REC_0014702 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.2 | 75 | female | 1 | 19 | 6.8 | 7 | pembrolizumab 200 mg q3w | 17.7 | true | MSS | 2026-03-15T05:36:00.893643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431861 | REC_0014703 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.9 | 73 | female | 1 | 19 | 3.9 | 2 | alectinib 600 mg BID | 21.4 | true | MSS | 2026-03-15T05:36:00.893922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863917 | REC_0014704 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 10 | 73 | female | 3 | 15 | 4.6 | 1 | osimertinib 80 mg daily | 10.4 | false | MSS | 2026-03-15T05:36:00.894367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233060 | REC_0014705 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.8 | 62 | male | 0 | 14 | 5.3 | 6 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:00.894690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404439 | REC_0014706 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 4.9 | 73 | female | 0 | 16 | 6.2 | 7 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:00.894970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599935 | REC_0014707 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 11.2 | 61 | male | 1 | 9 | 4.1 | 0 | entrectinib 600 mg daily | 40 | false | MSS | 2026-03-15T05:36:00.895259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293508 | REC_0014708 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 22 | 57 | male | 0 | 19 | 7.4 | 2 | alectinib 600 mg BID | 23.6 | false | MSS | 2026-03-15T05:36:00.895545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515174 | REC_0014709 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.7 | 76 | female | 2 | 52 | 4.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:36:00.895821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233524 | REC_0014710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 16.6 | 74 | male | 2 | 15 | 5.8 | 1 | osimertinib 80 mg daily | 16.1 | false | MSS | 2026-03-15T05:36:00.896136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237238 | REC_0014711 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.7 | 70 | female | 1 | 51 | 4 | 5 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:36:00.896436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406273 | REC_0014712 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 14.6 | 75 | female | 1 | 13 | 6.1 | 1 | osimertinib 80 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:00.896744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211070 | REC_0014713 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 9.7 | 63 | female | 1 | 23 | 4.5 | 0 | osimertinib 80 mg daily | 21.5 | true | MSS | 2026-03-15T05:36:00.897039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905553 | REC_0014714 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.6 | 77 | female | 1 | 19 | 3.6 | 1 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:36:00.897311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958926 | REC_0014715 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.7 | 69 | male | 0 | 10 | 6 | 2 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:36:00.897595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850852 | REC_0014716 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.4 | 83 | female | 0 | 4 | 4.9 | 6 | sotorasib 960 mg daily | 5.9 | false | MSI-H | 2026-03-15T05:36:00.897860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812339 | REC_0014717 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 17.5 | 69 | female | 0 | 22 | 4.6 | 6 | entrectinib 600 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:36:00.898293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638071 | REC_0014718 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7 | 78 | male | 1 | 37 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:36:00.898589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446365 | REC_0014719 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 31 | 15.1 | 59 | male | 0 | 13 | 4.2 | 0 | sotorasib 960 mg daily | 48.9 | false | MSI-H | 2026-03-15T05:36:00.898871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540426 | REC_0014720 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 11.1 | 65 | female | 1 | 14 | 4.8 | 1 | entrectinib 600 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:36:00.899189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507286 | REC_0014721 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 14.3 | 70 | male | 3 | 13 | 4.8 | 1 | alectinib 600 mg BID | 12.7 | true | MSI-H | 2026-03-15T05:36:00.899516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968740 | REC_0014722 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 12.4 | 63 | female | 0 | 17 | 5.6 | 0 | osimertinib 80 mg daily | 36.4 | false | MSS | 2026-03-15T05:36:00.899845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678624 | REC_0014723 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.9 | 78 | female | 2 | 14 | 5.8 | 7 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:36:00.900225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117826 | REC_0014724 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 8.3 | 69 | female | 0 | 50 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:36:00.900570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374981 | REC_0014725 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5.1 | 68 | male | 1 | 47 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 21 | true | MSS | 2026-03-15T05:36:00.900886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627470 | REC_0014726 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 9.7 | 57 | female | 1 | 15 | 4.3 | 1 | pembrolizumab 200 mg q3w | 31.6 | false | MSS | 2026-03-15T05:36:00.901222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874335 | REC_0014727 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.7 | 78 | female | 1 | 27 | 3.8 | 6 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:00.901527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924474 | REC_0014728 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 16.1 | 73 | male | 1 | 10 | 5.5 | 2 | sotorasib 960 mg daily | 20.1 | false | MSS | 2026-03-15T05:36:00.901834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994401 | REC_0014729 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.2 | 64 | female | 1 | 5 | 5.4 | 1 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:36:00.902140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147519 | REC_0014730 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 11.9 | 62 | female | 1 | 19 | 6.1 | 1 | sotorasib 960 mg daily | 24.4 | true | MSI-H | 2026-03-15T05:36:00.902619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828284 | REC_0014731 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.1 | 56 | male | 1 | 54 | 5.8 | 2 | pembrolizumab 200 mg q3w | 30.8 | true | MSS | 2026-03-15T05:36:00.902951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988040 | REC_0014732 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 7 | 67 | male | 0 | 13 | 6.9 | 5 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:36:00.903260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974601 | REC_0014733 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.8 | 59 | female | 0 | 24 | 6.5 | 6 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:00.903555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506862 | REC_0014734 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.8 | 60 | male | 1 | 46 | 7.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:36:00.903851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494199 | REC_0014735 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5 | 71 | female | 3 | 26 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSS | 2026-03-15T05:36:00.904206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182198 | REC_0014736 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 18.8 | 53 | male | 0 | 13 | 6.3 | 5 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:00.904534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269061 | REC_0014737 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 7.1 | 67 | male | 0 | 14 | 5 | 4 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:00.904841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586720 | REC_0014738 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.4 | 68 | female | 1 | 4 | 5.8 | 5 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:36:00.905136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468581 | REC_0014739 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 6.2 | 67 | female | 0 | 16 | 3 | 1 | pembrolizumab 200 mg q3w | 18.4 | false | MSS | 2026-03-15T05:36:00.905422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683968 | REC_0014740 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15 | 85 | female | 2 | 18 | 5.7 | 5 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:36:00.905734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951846 | REC_0014741 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 17.1 | 83 | female | 1 | 18 | 4.4 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSI-H | 2026-03-15T05:36:00.906043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410502 | REC_0014742 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.8 | 72 | female | 2 | 14 | 3.7 | 4 | entrectinib 600 mg daily | 16.9 | false | MSI-H | 2026-03-15T05:36:00.906366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994196 | REC_0014743 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.1 | 54 | female | 0 | 15 | 5.7 | 6 | entrectinib 600 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:36:00.906856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736777 | REC_0014744 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 69 | female | 1 | 44 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:00.907185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332255 | REC_0014745 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14.5 | 69 | female | 0 | 19 | 4.7 | 6 | osimertinib 80 mg daily | 7.3 | false | MSS | 2026-03-15T05:36:00.907511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235564 | REC_0014746 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 3.9 | 75 | female | 2 | 29 | 4.9 | 0 | pembrolizumab 200 mg q3w | 31.8 | true | MSS | 2026-03-15T05:36:00.907828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827506 | REC_0014747 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 14.1 | 70 | female | 1 | 9 | 4.2 | 0 | entrectinib 600 mg daily | 32.1 | true | MSI-H | 2026-03-15T05:36:00.908240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654018 | REC_0014748 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 2.4 | 67 | female | 1 | 23 | 4.5 | 5 | pembrolizumab 200 mg q3w | 5.1 | false | MSS | 2026-03-15T05:36:00.908562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627983 | REC_0014749 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 16.3 | 75 | female | 1 | 15 | 6.5 | 7 | sotorasib 960 mg daily | 7.9 | false | MSS | 2026-03-15T05:36:00.908896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243774 | REC_0014750 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.1 | 64 | female | 0 | 16 | 5.8 | 6 | sotorasib 960 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:36:00.909215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273377 | REC_0014751 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.8 | 69 | male | 0 | 17 | 5.3 | 4 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:36:00.909537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556458 | REC_0014752 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.3 | 72 | male | 1 | 58 | 6.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:36:00.909831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839602 | REC_0014753 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 10.6 | 68 | female | 0 | 12 | 5.4 | 5 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:36:00.910177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944701 | REC_0014754 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.2 | 59 | female | 1 | 40 | 7.3 | 6 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:36:00.910488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907241 | REC_0014755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 4.4 | 67 | female | 1 | 35 | 6.4 | 3 | pembrolizumab 200 mg q3w | 6.1 | false | MSS | 2026-03-15T05:36:00.910875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749262 | REC_0014756 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.2 | 70 | male | 2 | 14 | 3.2 | 1 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:36:00.911350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425542 | REC_0014757 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 9 | 71 | male | 1 | 24 | 4.4 | 4 | entrectinib 600 mg daily | 7 | false | MSS | 2026-03-15T05:36:00.911696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696324 | REC_0014758 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.2 | 70 | male | 2 | 2 | 5.3 | 8 | osimertinib 80 mg daily | 6.3 | true | MSS | 2026-03-15T05:36:00.912004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351383 | REC_0014759 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.2 | 69 | female | 1 | 51 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:36:00.912396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239120 | REC_0014760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 6.5 | 56 | female | 1 | 17 | 5.5 | 7 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:00.912713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405547 | REC_0014761 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.6 | 66 | male | 0 | 16 | 7.8 | 4 | sotorasib 960 mg daily | 19.3 | true | MSI-H | 2026-03-15T05:36:00.912986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615676 | REC_0014762 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.6 | 64 | male | 0 | 48 | 5.8 | 9 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:36:00.913247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281912 | REC_0014763 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8.9 | 64 | female | 1 | 31 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:00.913529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465085 | REC_0014764 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 14.4 | 81 | female | 2 | 9 | 5.2 | 2 | alectinib 600 mg BID | 14.8 | false | MSS | 2026-03-15T05:36:00.913806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655181 | REC_0014765 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 7.4 | 71 | female | 1 | 16 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:36:00.914100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659079 | REC_0014766 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 11.9 | 66 | female | 1 | 11 | 5.8 | 0 | entrectinib 600 mg daily | 30.2 | false | MSI-H | 2026-03-15T05:36:00.914401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290387 | REC_0014767 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.1 | 61 | male | 1 | 63 | 8.2 | 8 | pembrolizumab 200 mg q3w | 5.9 | true | MSS | 2026-03-15T05:36:00.914720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766658 | REC_0014768 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 1.5 | 71 | female | 0 | 10 | 6.4 | 0 | osimertinib 80 mg daily | 32 | true | MSS | 2026-03-15T05:36:00.915015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275841 | REC_0014769 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.2 | 68 | female | 1 | 16 | 5.5 | 2 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:36:00.915429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305285 | REC_0014770 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 10.6 | 77 | female | 2 | 15 | 5.1 | 1 | entrectinib 600 mg daily | 23.9 | false | MSI-H | 2026-03-15T05:36:00.915718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831306 | REC_0014771 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 19.5 | 53 | female | 0 | 14 | 7 | 2 | sotorasib 960 mg daily | 21.1 | false | MSI-H | 2026-03-15T05:36:00.915983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746528 | REC_0014772 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15.9 | 75 | male | 1 | 18 | 7.1 | 3 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:36:00.916312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835345 | REC_0014773 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 23 | 9.1 | 73 | female | 1 | 15 | 8.2 | 0 | pembrolizumab 200 mg q3w | 39.6 | true | MSS | 2026-03-15T05:36:00.916593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644050 | REC_0014774 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 17.7 | 57 | male | 1 | 11 | 5.4 | 1 | alectinib 600 mg BID | 17.6 | false | MSS | 2026-03-15T05:36:00.916882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650804 | REC_0014775 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 16.4 | 72 | female | 2 | 15 | 5.4 | 6 | alectinib 600 mg BID | 8.9 | false | MSI-H | 2026-03-15T05:36:00.917171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306805 | REC_0014776 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 8.4 | 75 | female | 2 | 14 | 4.7 | 0 | osimertinib 80 mg daily | 33.1 | true | MSS | 2026-03-15T05:36:00.917441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225814 | REC_0014777 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 15.9 | 43 | female | 0 | 5 | 5.9 | 6 | osimertinib 80 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:36:00.917723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790865 | REC_0014778 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 9.9 | 58 | male | 1 | 9 | 4.6 | 1 | entrectinib 600 mg daily | 21.6 | false | MSS | 2026-03-15T05:36:00.918018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800658 | REC_0014779 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 7.2 | 70 | female | 2 | 7 | 5.3 | 6 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:36:00.918314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599729 | REC_0014780 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.6 | 82 | female | 2 | 12 | 2.9 | 6 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:00.918627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345310 | REC_0014781 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.4 | 76 | female | 1 | 43 | 6.5 | 6 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:36:00.918915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738988 | REC_0014782 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.1 | 72 | female | 2 | 23 | 6.1 | 2 | sotorasib 960 mg daily | 22.7 | true | MSS | 2026-03-15T05:36:00.919372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890738 | REC_0014783 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 15.7 | 73 | female | 1 | 9 | 3.9 | 2 | alectinib 600 mg BID | 29.1 | true | MSS | 2026-03-15T05:36:00.919734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519277 | REC_0014784 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 12 | 65 | female | 0 | 17 | 6.8 | 3 | sotorasib 960 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:36:00.920132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679855 | REC_0014785 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 14 | 16.7 | 71 | female | 0 | 23 | 4.2 | 7 | pembrolizumab 200 mg q3w | 8.4 | true | MSI-H | 2026-03-15T05:36:00.920533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254411 | REC_0014786 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.2 | 66 | male | 0 | 20 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:36:00.920892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678653 | REC_0014787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 8.6 | 63 | female | 1 | 15 | 5.2 | 10 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:36:00.921266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225156 | REC_0014788 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.7 | 72 | female | 3 | 20 | 6 | 5 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:36:00.921619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541374 | REC_0014789 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 17.1 | 58 | female | 0 | 19 | 4.5 | 5 | entrectinib 600 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:00.921969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580257 | REC_0014790 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 9.4 | 71 | female | 0 | 12 | 7.4 | 5 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.922298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897320 | REC_0014791 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.8 | 56 | male | 0 | 2 | 6.6 | 7 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:36:00.922650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994756 | REC_0014792 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.9 | 74 | female | 3 | 10 | 7.5 | 9 | sotorasib 960 mg daily | 11.2 | true | MSS | 2026-03-15T05:36:00.922988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983620 | REC_0014793 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 10.7 | 76 | female | 2 | 22 | 5.9 | 1 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:36:00.923315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346653 | REC_0014794 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 19.1 | 62 | female | 1 | 14 | 6.7 | 4 | alectinib 600 mg BID | 7.5 | false | MSS | 2026-03-15T05:36:00.923684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519691 | REC_0014795 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.8 | 60 | female | 0 | 14 | 3.6 | 2 | entrectinib 600 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:36:00.924280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815533 | REC_0014796 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 16.2 | 73 | female | 2 | 18 | 5.2 | 2 | osimertinib 80 mg daily | 23.8 | false | MSI-H | 2026-03-15T05:36:00.924681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638807 | REC_0014797 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 6.1 | 59 | male | 1 | 39 | 6.4 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:00.925050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803675 | REC_0014798 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.4 | 79 | female | 2 | 18 | 4.6 | 5 | osimertinib 80 mg daily | 5.5 | true | MSI-H | 2026-03-15T05:36:00.925403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284430 | REC_0014799 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 10.4 | 66 | female | 1 | 11 | 5.4 | 9 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.925758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862737 | REC_0014800 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.2 | 63 | male | 1 | 13 | 4.1 | 6 | sotorasib 960 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:36:00.926115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.